Generative AI Models for Automated Drug Discovery and Design: Implications for Business and Management in the Pharmaceutical Industry

Abstract

Generative AI models are emerging as powerful tools in the field of drug discovery and design, offering innovative solutions to accelerate the development of novel therapeutics. This paper explores the application of generative AI techniques, such as generative adversarial networks (GANs), variational autoencoders (VAEs), and reinforcement learning, in the automated generation of molecular structures with desired properties. By leveraging large chemical databases and advanced machine learning algorithms, generative AI models can predict and design drug-like compounds, optimize molecular interactions, and suggest potential candidates for clinical trials, significantly reducing the time and cost involved in traditional drug discovery processes. Additionally, generative AI models can help address challenges in drug design, such as toxicity prediction, bioavailability enhancement, and the identification of novel drug targets. This paper also discusses the challenges and limitations of using generative AI in drug discovery, including data quality, model interpretability, and the need for high-quality, diverse datasets. The study concludes by highlighting the future potential of integrating generative AI with other cutting-edge technologies, such as high-throughput screening and quantum computing, to revolutionize the drug discovery pipeline and pave the way for personalized, precision medicine.